Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease
| Autor: | Akiko Kameda, Kazutaka Aoki, Eiko Yoshida, Atsushi Nakajima, Yu Togashi, Kazuki Tajima, Noriko Nishimiya, Kento Imajo, Daisuke Utsunomiya, Yasuo Terauchi, Tomio Inoue |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Adipose tissue Type 2 diabetes Gastroenterology chemistry.chemical_compound sodium-glucose co-transporter type-2 (SGLT2) inhibitor Insulin resistance Internal medicine Internal Medicine medicine Humans Prospective Studies skeletal muscle Canagliflozin Muscle Skeletal business.industry Fatty liver non-alcoholic fatty liver disease imaging General Medicine medicine.disease Magnetic Resonance Imaging adipose tissue chemistry Diabetes Mellitus Type 2 Liver Original Article Glycated hemoglobin Steatosis Transient elastography business medicine.drug |
| Zdroj: | Internal Medicine |
| ISSN: | 1349-7235 0918-2918 |
| Popis: | Objective We assessed the effect of canagliflozin, an sodium-glucose co-transporter type-2 inhibitor, on hepatic steatosis using three imaging modalities: magnetic resonance imaging (MRI), computed tomography, and transient elastography. We further determined factors associated with improving hepatic steatosis by canagliflozin among patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Methods We conducted a six-month prospective single-arm study between August 2015 and June 2017. The primary outcome was the change in hepatic steatosis assessed using the hepatic proton density fat fraction (PDFF) on MRI before and after treatment with canagliflozin. The secondary outcomes were changes in measures of glucose metabolism, including the hepatic glucose uptake on fluorodeoxyglucose-positron emission tomography, and the inflammation and volumes of visceral and subcutaneous adipose tissue and skeletal muscle. Patients Nine patients with type 2 diabetes and NAFLD completed this study. All participants received canagliflozin at a dose of 100 mg daily. Results Canagliflozin caused a significant reduction in hepatic PDFF from baseline [median 20.6% (interquartile range 11.7%, 29.8%)] after 6 months [10.6% (5.4%, 22.6%), p=0.008]. Canagliflozin also significantly reduced the body weight, glycated hemoglobin, homeostasis model assessment of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hs-CRP), and volumes of adipose tissue and skeletal muscle (all p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|